More broadly, this indicates a potential strategy to refine the predictive ability of gene expression-based signatures of chemosensitivity in breast cancer by first identifying cohorts based on relevant tumor biology such as ER, HER2 and Topoisomerase IIA expression. This evidence concerns the gene ERBB2 and breast carcinoma.